These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25485495)

  • 21. Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.
    Chen M; Turhan AG; Ding H; Lin Q; Meng K; Jiang X
    Oncotarget; 2017 Jul; 8(27):43662-43677. PubMed ID: 28599273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
    Jin B; Wang C; Shen Y; Pan J
    Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.
    Inselmann S; Wang Y; Saussele S; Fritz L; Schütz C; Huber M; Liebler S; Ernst T; Cai D; Botschek S; Brendel C; Calogero RA; Pavlinic D; Benes V; Liu ET; Neubauer A; Hochhaus A; Burchert A
    Cancer Res; 2018 Nov; 78(21):6223-6234. PubMed ID: 30166420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia].
    Shi DY; Qin YZ; Lai YY; Shi HX; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):469-476. PubMed ID: 32654459
    [No Abstract]   [Full Text] [Related]  

  • 26. Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells.
    Shinohara H; Kumazaki M; Minami Y; Ito Y; Sugito N; Kuranaga Y; Taniguchi K; Yamada N; Otsuki Y; Naoe T; Akao Y
    Cancer Lett; 2016 Feb; 371(1):1-11. PubMed ID: 26607903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
    Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
    Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
    Kayabasi C; Okcanoglu TB; Yelken BO; Asik A; Susluer SY; Avci CB; Saydam G; Gunduz C
    Gene; 2017 Dec; 637():173-180. PubMed ID: 28942039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells.
    Baykal-Köse S; Acikgoz E; Yavuz AS; Gönül Geyik Ö; Ateş H; Sezerman OU; Özsan GH; Yüce Z
    PLoS One; 2020; 15(2):e0229104. PubMed ID: 32106243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
    Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
    Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
    Kesarwani M; Kincaid Z; Gomaa A; Huber E; Rohrabaugh S; Siddiqui Z; Bouso MF; Latif T; Xu M; Komurov K; Mulloy JC; Cancelas JA; Grimes HL; Azam M
    Nat Med; 2017 Apr; 23(4):472-482. PubMed ID: 28319094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
    Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
    PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia.
    Valent P; Deininger M
    Leuk Lymphoma; 2008 Apr; 49(4):604-9. PubMed ID: 18398718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells.
    Ma L; Pak ML; Ou J; Yu J; St Louis P; Shan Y; Hutchinson L; Li S; Brehm MA; Zhu LJ; Green MR
    Proc Natl Acad Sci U S A; 2019 May; 116(21):10482-10487. PubMed ID: 31068472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New strategies in controlling drug resistance in chronic myeloid leukemia.
    Frame D
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.